Nachrichten

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

CNBC

Hims & Hers Health on Wednesday said it will offer five formulations of peptides and longevity treatments compounded in the U.S. as part of the initial rollout of its Peptides+ platform, all of which are not approved by regulators. Even as it announced the new products, Hims & Hers acknowledged it has more to learn about how best to use the peptides and how effective they are — underscoring the uncertainty surrounding the growing space. The new offerings come after the federal government eased restrictions on compounding certain unapproved peptides, which are short chains of amino ​acids.

Vollstaendiges Veytics-Briefing lesen

Wir zeigen den wichtigsten Punkt oeffentlich. Erstellen Sie ein kostenloses Konto, um den vollstaendigen Artikel zu lesen, ihn zu speichern, zu diskutieren und mit Markt- und OSINT-Kontext zu verbinden.